Prognostic significance of p53 Codon 72 polymorphism differs with race in colorectal adenocarcinoma

Clinical Cancer Research

Volumn 15, Issue 7, 2009, Pages 2406-2416

  Katkoori, Venkat R ^a   Jia, Xu ^a   Shanmugam, Chandrakumar ^a   Wan, Wen ^b   Meleth, Sreelatha ^b   Bumpers, Harvey ^c   Grizzle, William E ^a   Manne, Upender ^a,d  

^a Departments of Pathology   (United States)

^b UNIVERSITY OF ALABAMA SCHOOL OF MEDICINE   (United States)

^c MOREHOUSE SCHOOL OF MEDICINE   (United States)

^d University of Alabama at Birmingham   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARGININE; PROLINE; PROTEIN P53;

ADULT; AFRICAN AMERICAN; AGED; ARTICLE; CAUCASIAN; CLINICAL FEATURE; CODON; COLORECTAL ADENOMA; COLORECTAL CARCINOMA; CONFIDENCE INTERVAL; CORRELATION ANALYSIS; ETHNICITY; FEMALE; GENE; GENE FREQUENCY; GENE MUTATION; GENETIC POLYMORPHISM; GENOTYPE; HAZARD RATIO; HISPANIC; HUMAN; KAPLAN MEIER METHOD; LOG RANK TEST; MAJOR CLINICAL STUDY; MALE; METASTASIS; MISSENSE MUTATION; MORTALITY; MUTATION RATE; P53 GENE; PHENOTYPE; PRIORITY JOURNAL; PROGNOSIS; PROPORTIONAL HAZARDS MODEL; RACE; SURVIVAL;

ADENOCARCINOMA; AFRICAN AMERICANS; AGED; AMINO ACID SUBSTITUTION; CODON; COLORECTAL NEOPLASMS; EUROPEAN CONTINENTAL ANCESTRY GROUP; FEMALE; GENES, P53; HUMANS; MALE; MIDDLE AGED; MUTATION; POLYMORPHISM, SINGLE NUCLEOTIDE; PROGNOSIS; SURVIVAL ANALYSIS;

EID: 65249100166     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-08-1719     Document Type: Article

References (66)

1. Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2008. CA Cancer J Clin 2008;58:71 -96.
2. Mandelblatt J, Andrews H, Kao R, Wallace R, Kerner J. The late-stage diagnosis of colorectal cancer: demographic and socioeconomic factors. Am J Public Health 1996;86:1794-7.
3. Marcella S, Miller JE. Racial differences in colorectal cancer mortality. The importance of stage and socioeconomic status. J Clin Epidemiol 2001; 54:359-66.
4. Alexander D, Jhala N, Chatla C, et al. High-grade tumor differentiation is an indicator of poor prognosis in African Americans with colonic adenocarcinomas. Cancer 2005;103:2163-70.
5. Polite BN, Dignam JJ, Olopade OI. Colorectal cancer model of health disparities: understanding mortality differences in minority populations. J Clin Oncol 2006;24:2179-87.
6. Alexander DD, Waterbor J, Hughes T, Funkhouser E, Grizzle W, Manne U. African-American and Caucasian disparities in colorectal cancer mortality and survival by data source: an epidemiologic review. Cancer Biomark2007;3:301 -13.
7. Greenblatt MS, Bennett WP, Hollstein M, Harris CC. Mutations in the p53 tumor suppressor gene: clues to cancer etiology and molecular pathogenesis. CancerRes1994;54:4855-78.
8. Powell B, Soong R, lacopetta B, Seshadri R, Smith DR. Prognostic significance of mutations to different structural and functional regions of the p53 gene in breast cancer. Clin Cancer Res 2000;6:443 -51.
9. Goh HS, Chan CS, Khine K, Smith DR. p53 and behaviour of colorectal cancer. Lancet 1994;344: 233-4.
10. AasT, Borresen AL, Geisler S, et al. Specific P53 mutations are associated with de novo resistance to doxorubicin in breast cancer patients. Nat Med 1996; 2:811 -4.
11. Kressner U, Inganas M, Byding S, et al. Prognostic value of p53 genetic changes in colorectal cancer. J Clin Oncol 1999;17:593-9.
12. Skaug V, Ryberg D, Kure EH, et al. p53 mutations in defined structural and functional domains are related to poor clinical outcome in non-small cell lung cancer patients. Clin Cancer Res 2000;6:1031 -7.
13. Borresen AL, Andersen Tl, Eyfjord JE, et al. TP53 mutations and breast cancer prognosis: particularly poor survival rates for cases with mutations in the zinc-binding domains. Genes Chromosomes Cancer 1995;14:71 -5.
14. Erber R, Conradt C, Homann N, et al. TP53 DNA contact mutations are selectively associated with allelic loss and have a strong clinical impact in head and neck cancer. Oncogene1998;16:1671 -9.
15. 15.Vos M, Adams CH,VictorTC, van Helden PD. Polymorphisms and mutations found in the regions flanking exons 5 to 8 of theTP53 gene in a population at high risk for esophageal cancer in South Africa. Cancer Genet Cytogenet 2003;140:23-30.
16. Felley-Bosco E,Weston A,CawleyHM,Bennett WP, Harris CC. Functional studies of a germ-line polymorphism at codon 47 within the p53 gene. Am J Hum Genet1993;53:752-9.
17. Matlashewski GJ, Tuck S, Pim D, Lamb P, Schneider J, Crawford LV. Primary structure polymorphism at amino acid residue 72 of human p53. Mol Cell Biol 1987;7:961 -3.
18. Carbone D, Chiba I, Mitsudomi T. Polymorphism at codon 213 within the p53 gene. Oncogene 1991;6: 1691 -2.
19. Buchman VL, Chumakov PM, Ninkina NN, Samarina OP, Georgiev GP. A variation in the structure of the protein-coding region of the human p53 gene. Gene 1988;70:245-52.
20. Futreal PA, BarrettJC,Wiseman RW. An Alu polymorphism intragenic to theTP53 gene. Nucleic Acids Res1991;19:6977.
21. Oliva MR, Saez GT, Latres E, Cordon-Cardo C. A newpolymorphic siteinintron 2 ofTP53 characterizes LOH in human tumors by PCR-SSCP. Diagn Mol Pathol 1995;4:54-8.
22. LazarV, Hazard F, Bertin F, Janin N, Bellet D, Bressac B. Simple sequence repeat polymorphism within thep53 gene. Oncogene1993;8:1703-5.
23. Chumakov PM, Jenkins JR. BstNI/Ncil polymorphism of the human p53 gene (TP53). Nucleic Acids Res1991;19:6969.
24. McDanielT, CarboneD,Takahashi T, et al.TheMspI polymorphism in intron 6 of p53 (TP53) detected by digestion of PCR products. Nucleic Acids Res 1991; 19:4796.
25. ProsserJ,CondieA. BiallelicApaI polymorphism of the human p53 gene(TP53). NucleicAcidsRes1991; 19:4799.
26. Graf J, Merk B, Maurer U, Muller E, Bergmann L. Identification of novel polymorphisms in intron 7 of the human p53 gene in acute myeloid leukemia and healthydonors. Leuk Lymphoma 2001;41:655-8.
27. Graziani D, Romagnoli S, Cassani B, Alfano RM, Roncalli M, Coggi G. An Ava I polymorphism in the TP53 gene. Mol Cell Probes1999;13:393-5.
28. Dumont P, Leu JI, Della Pietra AC III, George DL, Murphy M. The codon 72 polymorphic variants of p53 have markedly different apoptotic potential. Nat Genet 2003;33:357-65.
29. Pim D,BanksL. p53 polymorphic variants at codon 72 exert different effects on cell cycle progression. Int J Cancer 2004;108:196-9.
30. Wu X, Zhao H, Amos CI, et al. p53 genotypes and haplotypes associated with lung cancer susceptibility and ethnicity. J Natl CancerInst2002;94:681 -90.
31. Lung FW, LeeTM, Shu BC, Chang FH. p53 codon 72 polymorphism and susceptibility malignancy of colorectal cancer in Taiwan. J Cancer Res Clin Oncol 2004;130:728-32.
32. Langerod A, Bukholm IR,BregardA,etal.TheTP53 codon 72 polymorphism may affect the function of TP53 mutations in breast carcinomas but not in colorectal carcinomas. Cancer Epidemiol Biomarkers Prev 2002;11:1684-8.
33. Hu Y, McDermott MP, Ahrendt SA. The p53 codon 72 proline allele is associated with p53 gene mutations in non-small cell lung cancer. Clin Cancer Res 2005;11:2502-9.
34. Shao Y,Tan W, Zhang S. p53 gene codon 72 polymorphism and risk of esophageal squamous cell carcinoma: a case/control study in a Chinese population. Dis Esophagus2008;21:139-43.
35. WangYC, Lee HS, Chen SK, ChangYY, Chen CY. Prognostic significance of p53 codon 72 polymorphism in lung carcinomas. Eur J Cancer 1999;35:226-30.
36. Compton CC, Fielding LP, Burgart LJ, et al. Prognostic factors in colorectal cancer. College of American Pathologists Consensus Statement 1999. Arch Pathol Lab Med 2000;124:979-94.
37. Green FL,PageDL,FlemingID, et al. American Joint Committee on Cancer. Cancer staging handbook from the AJCC cancer staging manual. 6th ed. New York: Springer-Verlag; 2006.
38. WHO. International classification of diseases for oncology. Geneva: World Health Organization;1990.
39. Fredricks DN, Relman DA. Paraffin removal from tissue sections for digestion and PCR analysis. Biotech-niques1999;26:198-200.
40. Friend S. p53: a glimpse at the puppet behind the shadow play. Science1994;265:334-5.
41. Brooks LA,TidyJA, Gusterson B, et al. Preferential retention of codon 72 arginine p53 in squamous cell carcinomas of the vulva occurs in cancers positive and negative for human papillomavirus. Cancer Res 2000;60:6875-7.
42. Fleiss J. Statistical methods for rates and proportions. NewYork(NY): John Wiley and Sons;1981.
43. Allison P. Survival analysis using the SAS System: a practical guide. Cary (NC): SAS Institute Inc;1995.
44. Kaplan E, Meier P. Non-parametric estimation from incomplete observations. J Am Stat Assoc 1958;53:457-81.
45. Cox DR. Regression models and life tables. J Roy StatSoc1972;34:187-220.
46. Mooney CZ, Duval RD. Bootstrapping: a non-parametric approach to statistical inference. Newbury Park (CA): Sage;1993.
47. Troisi RJ, Freedman AN, Devesa SS. Incidence of colorectal carcinoma in the U S.: an update of trends by gender, race, age, subsite, and stage,1975-1994. Cancer1999;85:1670-6.
48. Ozick LA, Jacob L, Donelson SS, Agarwal SK, Freeman HP. Distribution of adenomatous polyps in African-Americans. Am J Gastroenterol 1995;90: 758-60.
49. Alexander D, Chatla C, Funkhouser E, Meleth S, Grizzle WE, Manne U. Postsurgical disparity in survival between African Americans and Caucasians with colonic adenocarcinoma. Cancer 2004;101: 66-76.
50. Mayberry RM, Coates RJ, Hill HA, et al. Determinants of black/white differences in colon cancer survival. J Natl Cancer Inst1995;87:1686-93.
51. Devesa SS, Chow WH.Variation in colorectal cancer incidence in the United States by subsite of origin. Cancer1993;71:3819-26.
52. Gapstur SM, Potter JD, Folsom AR. Alcohol consumption and colon and rectal cancer in postmenopausal women. Int J Epidemiol 1994;23:50-7.
53. Slattery ML, Schaffer D, Edwards SL, Ma KN, Potter JD. Are dietary factors involved in DNA methylation associated with colon cancer? Nutr Cancer 1997;28: 52-62.
54. Holt PR, Mokuolu AO, Distler P, Liu T, Reddy BS. Regional distribution of carcinogen-induced colonic neoplasia in the rat. Nutr Cancer1996;25:129-35.
55. Hong MY, Chapkin RS, Morris JS, et al. Anatomical site-specific response to DNA damage is related to later tumor development in the rat azoxymethane colon carcinogenesis model. Carcinogenesis 2001; 22:1831 -5.
56. Maxwell GL, Risinger JI, Hayes KA, et al. Racial disparity in the frequency of PTEN mutations, but not microsatellite instability,inadvanced endometrial cancers. Clin Cancer Res 2000;6:2999-3005.
57. Hamelin R, Laurent-Puig P, Olschwang S, et al. Association of p53 mutations with short survival in colorectal cancer. Gastroenterology1994;106:42- 8.
58. Manne U, Myers RB, Moron C, et al. Prognostic significance of Bcl-2 expression and p53 nuclear accumulation in colorectal adenocarcinoma. Int J Cancer 1997;74:346-58.
59. Cho Y, Gorina S, Jeffrey PD, Pavletich NP. Crystal structure of a p53 tumor suppressor-DNA complex: understanding tumorigenic mutations. Science1994; 265:346-55.
60. Li X, Dumont P, Della Pietra A, Shetler C, Murphy ME. Thecodon 47 polymorphisminp53 isfunctionally significant. J Biol Chem 2005;280:24245-51.
61. Pinto GR,Yoshioka FK, Silva RL, et al. Prognostic valueofTP53 Pro47Serand Arg72Pro single nucleotide polymorphisms and the susceptibility to gliomas in individuals from Southeast Brazil. Genet Mol Res 2008;7:207-16.
62. Sjalander A, Birgander R, Athlin L, et al. P53 germ line haplotypes associated with increased risk for colorectal cancer. Carcinogenesis 1995;16: 1461 -4.
63. Marin MC, Jost CA, Brooks LA, et al. A common polymorphism acts as an intragenic modifier of mutant p53 behaviour. Nat Genet 2000;25:47-54.
64. JinX, WuX,Roth JA, et al.Higher lung cancerrisk for younger African-Americans with the Pro/Pro p53 genotype. Carcinogenesis1995;16:2205-8.
65. Schneider-Stock R, Boltze C, Peters B, et al. Selective loss of codon 72 proline p53 and frequent mutational inactivation of the retained arginine allele in colorectal cancer. Neoplasia 2004;6: 29-35.
66. Furihata M,Takeuchi T, Matsumoto M, et al. p53 mutation arising in Arg72 allele in the tumorigenesis and development of carcinoma of the urinary tract. Clin CancerRes2002;8:1192-5.